Cell Genesys — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Cell Genesys appears in 12 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials12

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

12 shown

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer PatientsNCT00133224 · lead sponsor · 2005-07-01

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate CancerNCT00103428 · lead sponsor · 2004-08-01

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate CancerNCT00089856 · lead sponsor · 2004-07-01

A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)NCT00089726 · lead sponsor · 2003-03-01

Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer VaccineNCT00140348 · lead sponsor · 2001-12-01

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)NCT00140387 · lead sponsor · 1999-05-01

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate CancerNCT00140400 · lead sponsor · 1999-05-01

Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)NCT00140374 · lead sponsor · 1998-12-01

Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate CancerNCT00116155 · lead sponsor

Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate CancerNCT00577356 · collaborator · 2008-02-01

GVAX in Advanced Prostate Cancer Patients Made LymphopenicNCT00122005 · collaborator · 2005-07-01

Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate CancerNCT01510288 · collaborator · 2004-11-01

Sponsor roles

lead sponsor9

collaborator3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.